Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
XHG · Nasdaq · United States · Insurance Agents, Brokers & Service
In shortXChange TEC.INC is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it. Bank or insurer: tests that do not apply to them are left out.
| Operating marginShare of each sale left after running the business, before interest and tax. | -197.2% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -204.9% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -3.2% | n/a |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | n/a |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 3 | 0/100 |
| Revenue growth volatility | 32.3% | 0/100 |
| Operating margin volatility | 113.9% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -17.6% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
CNY millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,036 | 652 | – | 288 | 365 |
| Cost of revenue | 950 | 711 | – | 275 | 357 |
| Gross profit | 87 | (59) | – | 13 | 8 |
| Research & development | 7.8 | 0 | 0 | 0 | – |
| Operating income | (27) | (29) | (24) | (589) | (720) |
| Interest expense | 103 | 42 | 1.6 | 26 | 28 |
| Pre-tax income | (131) | (495) | (25) | (613) | (748) |
| Income tax | 0 | 0 | – | 0.5 | 0 |
| Net income | (569) | 820 | (71) | (227) | (748) |
| Diluted EPS | ¥0.00 | ¥0.00 | ¥0.00 | ¥0.00 | ¥0.00 |
| Diluted shares (millions) | 146,069 | 1,025,842 | 28 | 238 | 50,254 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: the model does not apply to banks and insurers.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Sep 30, 2025 · Data updated Jul 16, 2026